State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P.R. China.
Mol Cancer Res. 2024 Jul 2;22(7):642-655. doi: 10.1158/1541-7786.MCR-23-0720.
Hepatitis B viral (HBV) persistent infection plays a significant role in hepatocellular carcinoma (HCC) tumorigenesis. Many studies have revealed the pivotal roles of N6-methyladenosine (m6A) in multiple cancers, while the regulatory mechanism in stemness maintenance of HBV persistent infection-related HCC remains elusive. Here, we demonstrated that the level of m6A modification was downregulated by HBV in HBV-positive HCC, through enhanced stability of ALKBH5 mRNA. More specifically, we also identified that ALKBH5 mRNA was functionally required for the stemness maintenance and self-renewal in the HBV-positive HCC, but dispensable in HBV-negative HCC. Mechanistically, ALKBH5 demethylated the m6A modification in the 3' untranslated region of the oncogenic gene SNAI2 to prevent the recognition of YTHDF2 therewith stabilize SNAI2 transcripts, contributing to cancer stem cell traits in HBV-positive HCC. Moreover, the expression of SNAI2 reversed the suppression of stemness properties by knocking down ALKBH5. In addition, ALKBH5/SNAI2 axis accelerates tumor immune evasion through activated ligand of immune checkpoint CD155. Our study unveiled that the ALKBH5 induces m6A demethylation of the SNAI2 as a key regulator in HBV-related HCC, and identifies the function of ALKBH5/SNAI2/YTHDF2 axis in promoting the stem-like cells phenotype and immune escape during HBV infection.
HBV promotes HCC stemness maintenance through elevate m6A modification of SNAI2 in an ALKBH5-YTHDF2-dependent manner and increases the expression of the ligand of immune checkpoint CD155.
乙型肝炎病毒(HBV)持续感染在肝细胞癌(HCC)的发生中起着重要作用。许多研究表明,N6-甲基腺苷(m6A)在多种癌症中起关键作用,而在 HBV 持续感染相关 HCC 的干性维持的调控机制仍不清楚。在这里,我们证明 HBV 通过增强 ALKBH5 mRNA 的稳定性,下调 HBV 阳性 HCC 中的 m6A 修饰水平。更具体地说,我们还发现 ALKBH5 mRNA 是 HBV 阳性 HCC 干性维持和自我更新所必需的,但在 HBV 阴性 HCC 中是可有可无的。在机制上,ALKBH5 去甲基化致癌基因 SNAI2 的 3'非翻译区的 m6A 修饰,防止 YTHDF2 在那里识别,从而稳定 SNAI2 转录本,有助于 HBV 阳性 HCC 中的癌症干细胞特征。此外,SNAI2 的表达逆转了敲低 ALKBH5 对干性特性的抑制作用。此外,ALKBH5/SNAI2 轴通过激活免疫检查点 CD155 的配体加速肿瘤免疫逃逸。我们的研究揭示了 ALKBH5 作为 HBV 相关 HCC 的关键调节因子,诱导 SNAI2 的 m6A 去甲基化,并确定了 ALKBH5/SNAI2/YTHDF2 轴在促进 HBV 感染期间干细胞样细胞表型和免疫逃逸中的功能。
HBV 通过 ALKBH5-YTHDF2 依赖方式提高 SNAI2 的 m6A 修饰,增加免疫检查点 CD155 的配体表达,促进 HCC 干性维持。